Document is current
Any future updates will be listed below
-
Authors
Westcott, Peter M. K. https://orcid.org/0000-0001-9436-4857
Muyas, Francesc
Hauck, Haley
Smith, Olivia C. https://orcid.org/0000-0002-2788-9917
Sacks, Nathan J.
Ely, Zackery A.
Jaeger, Alex M.
Rideout, William M. III
Zhang, Daniel https://orcid.org/0000-0003-1026-0976
Bhutkar, Arjun
Beytagh, Mary C. https://orcid.org/0000-0002-1882-1515
Canner, David A.
Jaramillo, Grissel C.
Bronson, Roderick T.
Naranjo, Santiago
Jin, Abbey
Patten, J. J. https://orcid.org/0000-0002-9770-7525
Cruz, Amanda M.
Shanahan, Sean-Luc
Cortes-Ciriano, Isidro https://orcid.org/0000-0002-2036-494X
Jacks, Tyler https://orcid.org/0000-0001-5785-8911
- License Information
-
More Information
Article History
Received: 9 March 2023
Accepted: 7 August 2023
First Online: 14 September 2023
Competing interests
: T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-founder of Dragonfly Therapeutics and T2 Biosystems. He serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech and Skyhawk Therapeutics, and is the President of Break Through Cancer. None of these affiliations represents a conflict of interest with respect to the design or execution of the present study or interpretation of data presented in this manuscript. The Jacks laboratory also currently receives funding from the Johnson & Johnson Lung Cancer Initiative and the Lustgarten Foundation for Pancreatic Cancer Research, but this did not support the research described in the present study. All other authors declare no competing interests.
